Global Viral and Non-Viral Vector Manufacturing Market

1
Global Viral and Non-Viral Vector Manufacturing
Market
res
Table of Content
Focus on Vector Type, Application, Disease and
Region Analysis and Forecast 2021-2031 December
2021
2
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in- depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high- growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
Copyright 2021 BIS Research Inc. All Rights
Reserved. This document contains highly
confidential information and is the sole property
of BIS Research. Disclosing, copying,
circulating, quoting, or otherwise reproducing
any or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by or offered whether for sale or
otherwise to any third party.
1
3

• Table of Content
• Executive Summary.................................
  .........................................26
• 1. Product Definition ............................
  ..........................................36
• 1.1 Product Definition............................
  ..................................................
  ..............36
• 2. Scope of Study.................................
  ..........................................37
• 2.1 Overview......................................
  ..................................................
  ...................37
• 2.2 Segmentation of the Global Viral and
  Non-Viral Vector Manufacturing Market
  ..................................................
  ..................................................
  ...........38
• 2.3 Assumptions and Limitations...................
  ..................................................
  ....38
• 2.4 Key Questions Answered in This
  Report............................................
  ...........39
• 2.5 Base Year and Forecast Period
  ..................................................
  ....................40
• 3. Research Methodology ..........................
  ....................................41
• 3.1 Overview......................................
  ..................................................
  ...................41
• Global Viral and Non-Viral Vector Manufacturing
  Market Overview .................................
  ..................................................
  47
• 4.1 Market Overview ..............................
  ..................................................
  ..............47
• 4.2 Introduction to Vectors ......................
  ..................................................
  ...........48
• 4.3 Importance of Vectors ........................
  ..................................................
  ...........49
• 4.3.1 Viral Vectors ............................
  ..................................................
  ..................50
• 4.3.2 Non-Viral Vectors ........................
  ..................................................
  ..............51
• 4.4 Major Milestones in Vector Manufacturing......
  ..............................................52
  4.4.1 Manufacturing Process.......................
  ..................................................
  ......52

GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
4

• 4.6.2.1 Effect on Cell Therapy ...................
  ..................................................
  .................. 58
• 4.6.2.2 Effect on Gene Therapy....................
  ..................................................
  ............... 59
• 4.6.3 Interruption in Research and Clinical
  Development and Commercial Operation
  ..................................................
  ..................................................
  .60
• 4.6.3.1 Research and Clinical Development.........
  ..................................................
  ....... 60
• 4.6.3.2 Commercial Operation and Access
  ..................................................
  ................. 60
• 4.6.4 Effect of COVID-19 in Vaccine
  Manufacturing ....................................
  ......61
• Measures Taken to Address the Current Problem
  ...................................64
• Navigating Crisis Recovery and Looking to the
  Future ...........................65 5. Market
  Dynamics .........................................
  ..............................67 5.1 Impact
  Analysis .........................................
  ..................................................
  ....67 5.2 Overview.............................
  ..................................................
  ............................67 5.3 Market
  Drivers...........................................
  ..................................................
  .....68 5.3.1 Viral Vectors .....................
  ..................................................
  .........................68
• Rapid Uptake of Viral Vector to Develop
  Innovative Therapies ......................... 68
• Increasing Number of Clinical Studies for the
  Development of Gene
• Therapy ..........................................
  ..................................................
  ....... 69
• Favorable Funding Scenario for Vector-Based
  Therapies................................. 70
• 5.3.2 Non-Viral Vectors ........................
  ..................................................
  ..............71
• 5.3.2.1 Increasing Adoption of Nucleic Acid
  Therapeutics .....................................
  ....... 71 5.3.2.2 Rise in Synergistic
  Activities in the Market .........................
  ............................... 71 5.4 Market
  Restraints........................................
  ..................................................
  ...72 5.4.1 Viral Vectors .......................
  ..................................................
  .......................72 5.4.1.1 Unaffordable
  Cost of Gene Therapy .............................
  ..................................... 72
  5.4.1.2 High Manufacturing Cost of Viral Vectors
  ..................................................
  ........ 73
• 5.4.1.3 Complications Associated with
  Large-Scale Production of Viral Vectors
  .......... 74 5.4.2 Non-Viral Vectors
  ..................................................
  ......................................74
  5.4.2.1 Low Transfection Efficiency
  ..................................................
  ............................. 74 5.5 Market
  Opportunities.....................................
  ..................................................
  75 5.5.1 Viral Vectors ..........................
  ..................................................
  ....................75 5.5.1.1 Rise in Demand
  for Synthetic Genes...............................
  .................................. 75
  5.5.1.2 Emergence of Next-Generation Vectors
  ..................................................
  .......... 75

GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
3
5

• 5.5.2 Non-Viral Vectors ........................
  ..................................................
  ..............76
• 5.5.2.1 Limitation of Viral Vectors
  ..................................................
  ................................ 76
• 6. Industry Analysis .............................
  ..........................................77
• 6.1 Overview......................................
  ..................................................
  ...................77
• 6.2 Regulatory Scenario ..........................
  ..................................................
  ............79
• 6.3 Patent Landscape .............................
  ..................................................
  .............82
• 7. Competitive Landscape .........................
  ....................................86
• 7.1 Overview......................................
  ..................................................
  ...................86
• 7.2 Key Development and Strategies
  ..................................................
  .................87
• 7.2.1 Synergistic Activities ...................
  ..................................................
  .............88
• 7.2.2 Business Expansion .......................
  ..................................................
  ..........89
• 7.2.3 Product Launches .........................
  ..................................................
  ............90
• 7.2.4 Mergers and Acquisitions..................
  ..................................................
  .......90
• 7.2.5 Other Development ........................
  ..................................................
  ...........91
• 7.3 Market Share Analysis (by Company),
  2020..............................................
  ....92
• 7.4 Growth Share Analysis ........................
  ..................................................
  .........94
• Growth Share Analysis of the Global Viral and
  Non-Viral Vector Manufacturing Market (by
  Company) .........................................
  ...............94
• Growth Share Analysis of the Global Viral and
  Non-Viral Vector Manufacturing Market (by Vector
  Type) ............................................
  ........95
• 8. Global Viral and Non-Viral Vector
  Manufacturing Market (by Vector
  Type).............................................
  .................................97

GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
4
6

• 8.3 Non-Viral Vectors.............................
  ..................................................
  ............110
• 8.3.1 Plasmid DNA ...............................
  ..................................................
  .............111
• 8.3.2 Lipid-Based Non-Viral Vector
  ..................................................
  .................113
• 8.3.3 Polymer-Based Non-Viral Vector
  ..................................................
  ...........114
• 8.3.4 Other Non-Viral Vector (Peptide-Based and
  Hybrid/Combination) .......116
• Global Viral and Non-Viral Vector Manufacturing
  Market (by Disease) .............................
  ..................................................
  ... 118
• 9.1 Overview......................................
  ..................................................
  .................118
• 9.2 Cancer .......................................
  ..................................................
  ...................120
• 9.3 Genetic Disease ..............................
  ..................................................
  .............122
• 9.4 Infectious Disease ...........................
  ..................................................
  ............123
• 9.5 Cardiovascular Disease .......................
  ..................................................
  .......125
• 9.6 Other Diseases................................
  ..................................................
  .............127
• Global Viral and Non-Viral Vector Manufacturing
  Market (by Application) .........................
  ..................................................
  .. 129
• 10.1 Overview.....................................
  ..................................................
  ..................129
• 10.2 Gene Therapy.................................
  ..................................................
  ..............131
• 10.2.1 Viral Vector ..............................
  ..................................................
  ................132
• 10.2.2 Non-Viral Vector ..........................
  ..................................................
  ............134
• 10.3 Vaccinology..................................
  ..................................................
  ................136
• 10.3.1 Viral Vector ..............................
  ..................................................
  ................138

GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
5
7
11.1 Overview.....................................
..................................................
..................147 11.2 North America
..................................................
..............................................148
11.2.1 Overview ..................................
..................................................
................148 11.2.2 U.S.
..................................................
..................................................
.........149 11.2.2.1 Viral Vector
..................................................
..................................................
.. 151 11.2.2.2 Non-Viral Vector
..................................................
............................................
152 11.2.3 Canada ................................
..................................................
.....................153 11.2.3.1 Viral Vector
..................................................
..................................................
.. 154 11.2.3.2 Non-Viral Vector
..................................................
............................................
155 11.3 Europe ..................................
..................................................
........................156 11.3.1 Overview
..................................................
..................................................
156 11.3.2 Germany................................
..................................................
...................157 11.3.2.1 Viral Vector
..................................................
..................................................
.. 158 11.3.2.2 Non-Viral Vector
..................................................
............................................
159 11.3.3 U.K. ..................................
..................................................
.........................160 11.3.3.1 Viral
Vector ...........................................
..................................................
......... 161 11.3.3.2 Non-Viral Vector
..................................................
............................................
162 11.3.4 France.................................
..................................................
......................163 11.3.4.1 Viral Vector
..................................................
..................................................
.. 164 11.3.4.2 Non-Viral Vector
..................................................
............................................
165 11.3.5 Italy .................................
..................................................
..........................166 11.3.5.1 Viral
Vector ...........................................
..................................................
......... 167 11.3.5.2 Non-Viral Vector
..................................................
............................................
168 11.3.6 Switzerland ...........................
..................................................
...................168 11.3.6.1 Viral Vector
..................................................
..................................................
.. 170 11.3.6.2 Non-Viral Vector
..................................................
............................................
171 11.3.7 Belgium ...............................
..................................................
.....................171 11.3.7.1 Viral Vector
..................................................
..................................................
.. 173 11.3.7.2 Non-Viral Vector
..................................................
............................................
173 11.3.8 Spain..................................
..................................................
.......................174 11.3.8.1 Viral Vector
..................................................
..................................................
.. 175
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
6
8
11.3.8.2 Non-Viral Vector .......................
..................................................
..................... 176 11.3.9
Rest-of-Europe....................................
..................................................
.....176 11.3.9.1 Viral Vector
..................................................
..................................................
.. 178 11.3.9.2 Non-Viral Vector
..................................................
............................................
178 11.4 Asia-Pacific ............................
..................................................
......................179 11.4.1 Overview
..................................................
..................................................
179 11.4.2 China .................................
..................................................
.......................180 11.4.2.1 Viral Vector
..................................................
..................................................
.. 182 11.4.2.2 Non-Viral Vector
..................................................
............................................
182 11.4.3 Australia .............................
..................................................
......................183 11.4.3.1 Viral Vector
..................................................
..................................................
.. 185 11.4.3.2 Non-Viral Vector
..................................................
............................................
185 11.4.4 Japan .................................
..................................................
.......................186 11.4.4.1 Viral Vector
..................................................
..................................................
.. 187 11.4.4.2 Non-Viral Vector
..................................................
............................................
188 11.4.5 India .................................
..................................................
.........................188 11.4.5.1 Viral
Vector ...........................................
..................................................
......... 190 11.4.5.2 Non-Viral Vector
..................................................
............................................
191 11.4.6 South Korea ...........................
..................................................
..................191 11.4.6.1 Viral Vector
..................................................
..................................................
.. 193 11.4.6.2 Non-Viral Vector
..................................................
............................................
193 11.4.7 Singapore .............................
..................................................
....................194 11.4.7.1 Viral Vector
..................................................
..................................................
.. 195 11.4.7.2 Non-Viral Vector
..................................................
............................................
196 11.4.8 Rest-of-Asia-Pacific...................
..................................................
..............196 11.4.8.1 Viral Vector
..................................................
..................................................
.. 197 11.4.8.2 Non-Viral Vector
..................................................
............................................
198 11.5 Rest-of-the-World .......................
..................................................
.................199 11.5.1 Overview
..................................................
..................................................
199 11.5.1.1 Viral Vector .......................
..................................................
............................. 200 11.5.1.2 Non-Vir
al Vector .......................................
..................................................
..... 201
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
7
9
12. Company Profiles..............................
.......................................
202 12.1 Overview.................................
..................................................
......................202 12.2 Boehringer
Ingelheim ........................................
............................................203 12
.2.1 Company Overview ............................
..................................................
.....203 12.2.1.1 Role of Boehringer Ingelheim in
the Global Viral and Non-Viral Vector
Manufacturing Market..............................
..............................................
203 12.2.1.2 Product Portfolio
..................................................
............................................
203 12.2.2 SWOT Analysis .........................
..................................................
...............204 12.3 Catalent, Inc.
..................................................
................................................20
5 12.3.1 Company Overview ........................
..................................................
.........205 12.3.1.1 Role of Catalent, Inc. in
the Global Viral and Non-Viral Vector Manufacturin
g Market..........................................
..................................
205 12.3.1.2 Product Portfolio
..................................................
............................................
206 12.3.2 Financials ............................
..................................................
.....................207 12.3.3 Key Insights
about Financial Health of the Company
............................208 12.3.4 SWOT
Analysis .........................................
.................................................2
09 12.4 FUJIFILM Holdings Corporation
..................................................
.................210 12.4.1 Company Overview
..................................................
.................................210 12.4.1.1 Role
of FUJIFILM Holdings Corporation in the Global
Viral and Non-Viral Vector Manufacturing Market
..................................................
.............. 210 12.4.1.2 Product Portfolio
..................................................
............................................
211 12.4.2 Financials ............................
..................................................
.....................211 12.4.3 Key Insights
about Financial Health of the Company
............................213 12.4.4 SWOT
Analysis .........................................
.................................................2
14 12.5 Danaher Corporation ......................
..................................................
.............215 12.5.1 Company Overview
..................................................
.................................215 12.5.2 Role
of Danaher Corporation in the Global Viral and
Non-Viral Vector Manufacturing Market
..................................................
.................215 12.5.2.1 Product Portfolio
..................................................
............................................
216 12.5.3 Financials ............................
..................................................
.....................217 12.5.4 Key Insights
about Financial Health of the Company
............................218 12.5.5 SWOT
Analysis .........................................
.................................................2
19 8
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
10
12.6 Genscript Biotech Corporation
..................................................
..................220 12.6.1 Company Overview
..................................................
.................................220 12.6.1.1 Role
of Genscript Biotech Corporation in the Global
Viral and Non-Viral Vector Manufacturing Market
..................................................
.............. 220 12.6.1.2 Product Portfolio
..................................................
............................................
221 12.6.2 Financials ............................
..................................................
.....................221 12.6.3 Key Insights
about Financial Health of the Company
............................223 12.6.4 SWOT
Analysis .........................................
.................................................2
24 12.7 Lonza Group AG ..........................
..................................................
................225 12.7.1 Company Overview
..................................................
.................................225 12.7.1.1 Role
of Lonza Group AG in the Global Viral and
Non-Viral Vector Manufacturing Market.............
..................................................
............. 225 12.7.1.2 Product Portfolio
..................................................
............................................
226 12.7.2 Financials ............................
..................................................
.....................226 12.7.3 Key Insights
about Financial Health of the Company
............................228 12.7.4 SWOT
Analysis .........................................
.................................................2
29 12.8 Merck KGaA Inc. ..........................
..................................................
................230 12.8.1 Company Overview
..................................................
.................................230 12.8.1.1 Role
of Merck KGaA Inc. in the Global Viral and
Non-Viral Vector Manufacturing Market.............
..................................................
............. 230 12.8.1.2 Product Portfolio
..................................................
............................................
231 12.8.2 Financials ............................
..................................................
.....................231 12.8.3 Key Insights
about Financial Health of the Company
............................233 12.8.4 SWOT
Analysis .........................................
.................................................2
33 12.9 Oxford Biomedica plc......................
..................................................
............234 12.9.1 Company Overview
..................................................
.................................234 12.9.1.1 Role
of Oxford Biomedica plc in the Global Viral and
Non-Viral Vector Manufacturing
Market............................................
................................
234 12.9.1.2 Product Portfolio
..................................................
............................................
235 12.9.2 Financials ............................
..................................................
.....................235 12.9.3 Key Insights
about Financial Health of the Company
............................237 12.9.4 SWOT
Analysis .........................................
.................................................2
38 9
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
11
12.10 Sartorius AG...............................
..................................................
..................239 12.10.1 Company
Overview..........................................
...................................239 12.10.1.1
Role of Sartorius AG in the Global Viral and
Non-Viral Vector Manufacturing Market.............
..................................................
............. 239 12.10.1.2 Product Portfolio
..................................................
............................................
240 12.10.2 Financials ...........................
..................................................
...............240 12.10.3 Key Insights about
Financial Health of the Company...................
...242 12.10.4 SWOT Analysis.....................
..................................................
.............243 12.11 Takara Bio Inc.
..................................................
.............................................244
12.11.1 Company Overview..........................
..................................................
.244 12.11.1.1 Role of Takara Bio Inc. in the
Global Viral and Non-Viral Vector Manufacturing
Market............................................
................................ 244 12.11.1.2
Product Portfolio ................................
..................................................
............ 245 12.11.2 Financials
..................................................
..........................................245 12.1
1.3 Key Insights about Financial Health of the
Company......................247 12.11.4 SWOT
Analysis..........................................
..........................................248 12.1
2 Thermo Fisher Scientific Inc...................
..................................................
....249 12.12.1 Company Overview..................
..................................................
.........249 12.12.1.1 Role of Thermo Fisher
Scientific, Inc. in the Global Viral and
Non-Viral Vector Manufacturing Market
..................................................
.............. 249 12.12.1.2 Product Portfolio
..................................................
............................................
250 12.12.2 Financials ...........................
..................................................
...............251 12.12.3 Key Insights about
Financial Health of the Company...................
...252 12.12.4 SWOT Analysis......................
..................................................
............253 12.13 Wuxi AppTec
..................................................
................................................25
4 12.13.1 Company Overview........................
..................................................
...254 12.13.1.1 Role of Wuxi AppTec in Global
Viral and Non-Viral Vector Manufacturing
Market............................................
..................................................
...... 254 12.13.1.2 Product Portfolio
..................................................
............................................
255 12.13.2 Financials ...........................
..................................................
...............255 12.13.3 Key Insights about
Financial Health of the Company...................
...257 12.13.4 SWOT Analysis.....................
..................................................
.............258
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
12
12.14 Acuitas Therapeutics ......................
..................................................
............259 12.14.1 Company
Overview..........................................
...................................259 12.14.1.1
Role of Acuitas Therapeutics in the Global Viral
and Non-Viral Vector Manufacturing
Market............................................
................................ 259 12.14.1.2
Product Portfolio ................................
..................................................
............ 259 12.14.2 SWOT Analysis............
..................................................
......................260 12.15 Evonik
Industries AG ....................................
................................................26
1 12.15.1 Company Overview........................
..................................................
...261 12.15.1.1 Role of Evonik Industries AG in
the Global Viral and Non-Viral Vector
Manufacturing Market..............................
..............................................
261 12.15.1.2 Product Portfolio
..................................................
............................................
262 12.15.2 Financials ...........................
..................................................
...............262 12.15.3 Key Insights about
Financial Health of the Company...................
...264 12.15.4 SWOT Analysis......................
..................................................
............265 12.16 Exelead, Inc.
..................................................
.................................................2
66 12.16.1 Company Overview.......................
..................................................
....266 12.16.1.1 Role of Exelead, Inc. in the
Global Viral and Non-Viral Vector Manufacturing
Market............................................
................................ 266 12.16.1.2
Product Portfolio ................................
..................................................
............ 266 12.16.2 SWOT Analysis............
..................................................
......................267 12.17 Entos
Pharmaceuticals ..................................
...............................................268
12.17.1 Company Overview.........................
..................................................
..268 12.17.1.1 Role of Entos Pharmaceuticals in
the Global Viral and Non-Viral Vector
Manufacturing Market..............................
..............................................
268 12.17.1.2 Product Portfolio
..................................................
............................................
268 12.17.2 SWOT Analysis.........................
..................................................
.........269 12.18 Genevant Sciences GmbH
..................................................
..........................270 12.18.1 Company
Overview..........................................
...................................270 12.18.1.1
Role of Genevant Sciences GmbH in the Global
Viral and Non-Viral Vector Manufacturing Market
..................................................
.............. 270 12.18.1.2 Product Portfolio
..................................................
............................................
270 12.18.2 SWOT Analysis.........................
..................................................
.........271
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
13
12.19 TT Scientific Corporation
..................................................
.........................272 12.19.1 Company
Overview..........................................
...................................272 12.19.1.1
Role of TT Scientific Corporation in the Global
Viral and Non-Viral Vector Manufacturing Market
..................................................
.............. 272 12.19.1.2 Product Portfolio
..................................................
............................................
272 12.19.2 SWOT Analysis.........................
..................................................
.........273 12.20 Moderna, Inc..................
..................................................
...............................274 12.20.1 Company
Overview.........................................
....................................274 12.20.1.1
Role of Moderna, Inc. in the Global Viral and
Non-Viral Vector Manufacturing Market.............
..................................................
............. 274 12.20.1.2 Product Portfolio
..................................................
............................................
275 12.20.2 Financials ...........................
..................................................
...............276 12.20.3 Key Insights about
Financial Health of the Company...................
...277 12.20.4 SWOT Analysis......................
..................................................
............278 12.21 CureVac N.V.
..................................................
................................................27
9 12.21.1 Company Overview........................
..................................................
...279 12.21.1.1 Role of CureVac N.V in the
Global Viral and Non-Viral Vector Manufacturing
Market............................................
................................ 279 12.21.1.2
Product Portfolio ................................
..................................................
............ 279 12.21.2 Financials
..................................................
..........................................280 12.2
1.3 Key Insights about Financial Health of the
Company......................281 12.21.4 SWOT
Analysis..........................................
..........................................282
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
14
List of Figures
Figure 1 Figure 2 Figure 3
Global Viral and Non-Viral Vector Manufacturing
Market (by Region), 2020 and 2031 Key Players of
the Global Viral and Non-Viral Vector
Manufacturing Market Drivers, Challenges, and
Opportunities of the Global Viral Vector and
Non-Viral Vector Manufacturing Market Share of
Key Developments and Strategies, January
2018-October 2021 Global Viral and Non-Viral
Vector Manufacturing Market (by Vector Type),
Million, 2020 and 2031 Global Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031 Global Viral
and Non-Viral Vector Manufacturing Market (by
Disease), 2020 and 2031 Global Viral and
Non-Viral Vector Manufacturing Market (by
Application), 2020 and 2031 Global Viral and
Non-Viral Vector Manufacturing Market Segmentation
Figure 4 Figure 5
Figure 6
Figure 7 Figure 8 Figure 9
Figure 10 Global Viral and Non-Viral Vector
Manufacturing Market Research Methodology Figure
11 Primary Research Figure 12 Secondary
Research Figure 13 Data Triangulation Figure
14 Bottom-Up Approach (Segment-Wise Analysis)
Figure 15 Top-Down Approach (Segment-Wise
Analysis) Figure 16 Assumptions and
Limitations Figure 17 Mechanism of Action of
Vectors Figure 18 Evolutionary History of
Vectors Figure 19 Typical Production Methods of
Viral Vectors and Plasmids Figure 20 Global
Viral and Non-Viral Vector Manufacturing Market,
Billion, 2020-2031 Figure 21 Pre- COVID-19 and
Post-COVID-19 Scenario of the Global Viral and
Non-Viral Vector Manufacturing Market,
2017-2025 Figure 22 Long, Complex, and Highly
Controlled Supply Chain of Cell Therapy Figure
23 Less-Complex Supply Chain of Gene
Therapy Figure 24 Areas of Disruption in Cell
Therapy Industry Figure 25 Areas of Disruption
in Gene Therapy Industry Figure 26 Key Areas of
Disruption in Commercial Operation Figure 27
Measures to Navigate Crisis Recovery Figure 28
Impact Analysis Figure 29 Workflow Associated
with Biomanufacturing for the Commercialization
of Viral and Non- Viral Vector Products Figure
30 Competitive Landscape, January 2018-October
2021 Figure 31 Share of Key Development and
Strategy, January 2018-October 2021 Figure 32
Share of Synergistic Activities (by Company),
January 2018-October 2021 13
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
15
Figure 33 Share of Business Expansion Activities
(by Company), January 2018-October 2021 Figure
34 Share of Product Launches (by Company),
January 2018-October 2021 Figure 35 Share of
Mergers and Acquisitions (by Company), January
2018-October 2021 Figure 36 Share of Other Key
Developments (by Company), January 2018-October
2021 Figure 37 Market Share Analysis of Global
Viral and Non-Viral Vector Manufacturing Market
(by Company), 2020 Figure 38 Growth Share
Analysis for Global Viral and Non-Viral Vector
Manufacturing Market (by Company), 2020 Figure
39 Growth Share Analysis for the Global Viral
and Non-Viral Vector Manufacturing Market (by
Vector Type), 2020 Figure 40 Global Viral and
Non-Viral Vector Manufacturing Market
Segmentation (by Vector Type) Figure 41 Global
Viral and Non-Viral Vector Manufacturing Market
(by Viral and Non-Viral Vector), Million, 2020
and 2031 Figure 42 Global Viral and Non-Viral
Vector Manufacturing Market (by Viral Vector),
Million, 2020- 2031 Figure 43 Global Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031 Figure 44
Global Viral and Non-Viral Vector Manufacturing
Market for Adenoviral Vector Million,
2020-2031 Figure 45 Global Viral and Non-Viral
Vector Manufacturing Market for Retroviral Vector
Million, 2020- 2031 Figure 46 Global Viral and
Non-Viral Vector Manufacturing Market for
Adeno-Associated Viral Vector, Million,
2020-2031 Figure 47 Global Viral and Non-Viral
Vector Manufacturing Market for Lentiviral
Vector, 2020-2031 Figure 48 Global Viral and
Non-Viral Vector Manufacturing Market for
Vaccinia Viral Vector, Million, 2020-2031 Figure
49 Global Viral and Non-Viral Vector
Manufacturing Market for Other Viral Vector,
Million, 2020-2031 Figure 50 Global Viral and
Non-Viral Vector Manufacturing Market for
Non-Viral Vectors, 2020-2031 Figure 51 Global
Viral and Non-Viral Vector Manufacturing Market
(by Non-Viral Vector), Million, 2020 and
2031 Figure 52 Global Viral and Non-Viral Vector
Manufacturing Market for Plasmid DNA, Million,
2020- 2031 Figure 53 Different Types of
Lipid-Based Non-Viral Vectors Figure 54 Viral
and Non-Viral Vector Manufacturing Market for
Lipid-Based Non-Viral Vectors, Million,
2020-2031 Figure 55 Different Types of Polymers
Used as Delivery Systems Figure 56 Viral and
Non-Viral Vector Manufacturing Market for
Polymer-Based Non-Viral Vector, Million,
2020-2031 Figure 57 Viral and Non-Viral Vector
Manufacturing Market for Other Non-Viral Vector,
Million, 2020- 2031 14
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
16
Figure 58 Global Viral and Non-Viral Vector
Manufacturing Market Segmentation (by Disease)
Figure 59 Global Viral and Non-Viral Vector
Manufacturing Market (by Disease) Figure 60
Global Viral and Non-Viral Vector Manufacturing
Market for Cancer, Million, 2020-2031 Figure
61 List of Approved Human Gene Transfer Trials
for Monogenic Disorders Figure 62 Global Viral
and Non-Viral Vector Manufacturing Market for
Genetic Disease, Million, 2020-2031 Figure 63
Global Viral and Non-Viral Vector Manufacturing
Market for Infectious Disease, Million,
2020-2031 Figure 64 Global Viral and Non-Viral
Vector Manufacturing Market for Cardiovascular
Disease, Million, 2020-2031 Figure 65 Global
Viral and Non-Viral Vector Manufacturing Market
for Other Diseases, 2020-2031 Figure 66 Global
Viral and Non-Viral Vector Manufacturing Market
Segmentation (by Application) Figure 67 Global
Viral and Non-Viral Vector Manufacturing Market
(by Application), 2020 and 2031 Figure 68
Global Viral and Non-Viral Vector Manufacturing
Market for Gene Therapy, Million,
2020- 2031 Figure 69 Gene Therapy Viral Vs.
Non-Viral Vector Manufacturing Market, Million,
2020-2031 Figure 70 Global Viral and Non-Viral
Vector Manufacturing Market for Gene Therapy (by
Viral Vector), Million, 2020 and 2031 Figure 71
Global Viral and Non-Viral Vector Manufacturing
Market for Gene Therapy (by Non-Viral Vector),
Million, 2020 and 2031 Figure 72 Global Viral
and Non-Viral Vector Manufacturing Market for
Vaccinology, Million, 2020- 2031 Figure 73
Vaccinology Viral Vs. Non-Viral Vector
Manufacturing Market, Million, 2020-2031 Figure
74 Global Viral and Non-Viral Vector
Manufacturing Market for Vaccinology (by Viral
Vector), Million, 2020 and 2031 Figure 75
Global Viral and Non-Viral Vector Manufacturing
Market for Vaccinology (by Non-Viral Vector),
2020 and 2031 Figure 76 Global Viral and
Non-Viral Vector Manufacturing Market for Cell
Therapy, Million, 2020- 2031 Figure 77 Cell
Therapy Viral Vs. Non-Viral Vector Manufacturing
Market, Million, 2020-2031 Figure 78 Global
Viral and Non-Viral Vector Manufacturing Market
for Cell Therapy (by Viral Vector), Million,
2020 and 2031 Figure 79 Global Viral and
Non-Viral Vector Manufacturing Market for Cell
Therapy (by Non-Viral Vector), Million, 2020
and 2031 Figure 80 Global Viral and Non-Viral
Vector Manufacturing Market for Other
Applications, Million, 2020-2031 Figure 81
Other Applications Viral Vs. Non-Viral Vector
Manufacturing Market, Million, 2020-2031 Figure
82 Global Viral and Non-Viral Vector
Manufacturing Market for Other Applications (by
Viral Vector), Million, 2020 and 2031 Figure 83
Global Viral and Non-Viral Vector Manufacturing
Market for Other Applications (by Non-Viral
Vector), Million, 2020 and 2031 15
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
17
Figure 84 North America Viral and Non-Viral
Vector Manufacturing Market, Million, 2020-2031
Figure 85 U.S. Viral and Non-Viral Vector
Manufacturing Market, Million, 2020-2031 Figure
86 U.S. Viral and Non-Viral Vector
Manufacturing Market (Viral Vs. Non-Viral),
Million, 2020- 2031 Figure 87 U.S. Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031 Figure 88
U.S. Viral and Non-Viral Vector Manufacturing
Market (by Non-Viral Vector), Million, 2020 and
2031 Figure 89 Canada Viral and Non-Viral
Vector Manufacturing Market, Million,
2020-2031 Figure 90 Canada Viral and Non-Viral
Vector Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Figure 91
Canada Viral and Non-Viral Vector Manufacturing
Market (by Viral Vector), Million, 2020 and
2031 Figure 92 Canada Viral and Non-Viral
Vector Manufacturing Market (by Non-Viral
Vector), Million, 2020 and 2031 Figure 93
Europe Viral and Non-Viral Vector Manufacturing
Market, Million, 2020-2031 Figure 94 Germany
Viral and Non-Viral Vector Manufacturing Market,
Million, 2020-2031 Figure 95 Germany Viral and
Non-Viral Vector Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Figure 96
Germany Viral and Non-Viral Vector Manufacturing
Market (by Viral Vector), Million, 2020 and
2031 Figure 97 Germany Viral and Non-Viral
Vector Manufacturing Market (by Non-Viral
Vector), Million, 2020 and 2031 Figure 98
U.K. Viral and Non-Viral Vector Manufacturing
Market, Million, 2020-2031 Figure 99 U.K.
Viral Vs Non-Viral Vector Manufacturing Market
(Viral Vs. Non-Viral), Million, 2020- 2031
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
U.K. Viral and Non-Viral Vector Manufacturing
Market (by Viral Vector), Million, 2020 and
2031 U.K. Viral and Non-Viral Vector
Manufacturing Market (by Non-Viral Vector),
Million, 2020 and 2031 France Viral and
Non-Viral Vector Manufacturing Market, Million,
2020-2031 France Viral and Non-Viral Vector
Manufacturing Market (Viral Vs. Non-Viral),
Million, 2020-2031 France Viral and Non-Viral
Vector Manufacturing Market (by Viral Vector),
Million, 2020 and 2031 France Viral and
Non-Viral Vector Manufacturing Market (by
Non-Viral Vector), Million, 2020 and
2031 Italy Viral and Non-Viral Vector
Manufacturing Market, Million, 2020-2031 Italy
Viral and Non-Viral Vector Manufacturing Market
(Viral Vs. Non-Viral), 2020-2031 Italy Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031
Figure 100
Figure 101
Figure 102 Figure 103
Figure 104
Figure 105
Figure 106 Figure 107 Figure 108
18
Italy Viral and Non-Viral Vector Manufacturing
Market (by Non-Viral Vector), Million, 2020 and
2031 Switzerland Viral and Non-Viral Vector
Manufacturing Market, Million, 2020-2031
Switzerland Viral and Non-Viral Vector
Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Switzerland
Viral and Non-Viral Vector Manufacturing Market
(by Viral Vector), Million, 2020 and
2031 Switzerland Viral and Non-Viral Vector
Manufacturing Market (by Non-Viral
Vector), Million, 2020 and 2031 Belgium Viral
and Non-Viral Vector Manufacturing Market,
Million, 2020-2031 Belgium Viral and Non-Viral
Vector Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Belgium Viral
and Non-Viral Vector Manufacturing Market (by
Viral Vector), Million, 2020 and 2031 Belgium
Viral and Non-Viral Vector Manufacturing Market
(by Non-Viral Vector), 2020 and 2031 Spain
Viral and Non-Viral Vector Manufacturing Market,
Million, 2020-2031 Spain Viral and Non-Viral
Vector Manufacturing Market, (Viral Vs.
Non-Viral), Million, 2020-2031 Spain Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031 Spain Viral
and Non-Viral Vector Manufacturing Market (by
Non-Viral Vector), Million, 2020 and
2031 Rest-of-Europe Viral and Non-Viral Vector
Manufacturing Market, Million, 2020-2031
Rest-of-Europe Viral and Non-Viral Vector
Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Rest-of-Europe
Viral and Non-Viral Vector Manufacturing Market
(by Viral Vector), Million, 2020 and
2031 Rest-of-Europe Viral and Non-Viral Vector
Manufacturing Market (by Non-Viral
Vector), Million, 2020 and 2031 Asia-Pacific
Viral and Non-Viral Vector Manufacturing Market,
Million, 2020-2031 China Viral Vector and
Non-Viral Vector Manufacturing Market, Million
2020-2031 China Viral and Non-Viral Vector
Manufacturing Market (Viral Vs. Non-Viral),
Million, 2020-2031 China Viral and Non-Viral
Vector Manufacturing Market (by Viral Vector),
Million, 2020 and 2031 China Viral and
Non-Viral Vector Manufacturing Market (by
Non-Viral Vector), Million, 2020 and
2031 Australia Viral Vector and Non-Viral Vector
Manufacturing Market, Million 2020-2031
Australia Viral and Non-Viral Vector
Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031
Figure 109
Figure 110 Figure 111
Figure 112
Figure 113
Figure 114 Figure 115
Figure 116
Figure 117
Figure 118 Figure 119
Figure 120
Figure 121
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
Figure 122 Figure 123
Figure 124
Figure 125
Figure 126 Figure 127 Figure 128
Figure 129
Figure 130
Figure 131 Figure 132
19
Australia Viral and Non-Viral Vector
Manufacturing Market (by Viral Vector), Million,
2020 and 2031 Australia Viral and Non-Viral
Vector Manufacturing Market (by Non-Viral
Vector), Million, 2020 and 2031 Japan Viral
Vector and Non-Viral Vector Manufacturing Market,
Million 2020-2031 Japan Viral and Non-Viral
Vector Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Japan Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031 Japan Viral
and Non-Viral Vector Manufacturing Market (by
Non-Viral Vector), Million, 2020 and
2031 India Viral Vector and Non-Viral Vector
Manufacturing Market, Million 2020-2031 India
Viral vs Non-Viral Vector Manufacturing Market,
Million, 2020-2031 India Viral and Non-Viral
Vector Manufacturing Market (by Viral Vector),
Million, 2020 and 2031 India Viral and
Non-Viral Vector Manufacturing Market (by
Non-Viral Vector), Million, 2020 and 2031 South
Korea Viral Vector and Non-Viral Vector
Manufacturing Market, Million, 2020- 2031 South
Korea Viral and Non-Viral Vector Manufacturing
Market (Viral Vs. Non-Viral), Million,
2020-2031 South Korea Viral and Non-Viral Vector
Manufacturing Market (by Viral Vector), Million,
2020 and 2031 South Korea Viral and Non-Viral
Vector Manufacturing Market (by Non-Viral
Vector), Million, 2020 and 2031 Singapore Viral
Vector and Non-Viral Vector Manufacturing Market,
Million 2020-2031 Singapore Viral and
Non-Viral Vector Manufacturing Market (Viral Vs.
Non-Viral), Million, 2020-2031 Singapore Viral
and Non-Viral Vector Manufacturing Market (by
Viral Vector), Million, 2020 and
2031 Singapore Viral and Non-Viral Vector
Manufacturing Market (by Non-Viral
Vector), Million, 2020-2031 Rest-of-Asia-Pacific
Viral Vector and Non-Viral Vector Manufacturing
Market, Million, 2020-2031 Rest-of-Asia-Pacific
Viral and Non-Viral Vector Manufacturing Market
(Viral Vs. Non- Viral Vector), Million,
2020-2031 Rest-of-Asia-Pacific Viral and
Non-Viral Vector Manufacturing Market (by Viral
Vector), Million, 2020 and 2031 Rest-of-Asia-Paci
fic Viral and Non-Viral Vector Manufacturing
Market (by Non-Viral Vector), Million, 2020 and
2031 Rest-of-the-World Viral and Non-Viral Vector
Manufacturing Market, Million, 2020-2031
Figure 133
Figure 134
Figure 135 Figure 136
Figure 137
Figure 138
Figure 139 Figure 140 Figure 141
Figure 142
Figure 143
Figure 144
Figure 145
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
Figure 146
Figure 147 Figure 148
Figure 149
Figure 150
Figure 151
Figure 152
Figure 153
Figure 154
Figure 155
20
Figure 156 Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market (Viral Vs. Non-
Viral), Million, 2020-2031
Figure 157 Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market (by Viral Vector), Million, 2020 and 2031
Figure 158 Rest-of-the-World Viral and Non-Viral Vector Manufacturing Market (by Non-Viral Vector), Million, 2020 and 2031
Figure 159 Shares of Key Company Profiles
Figure 160 Boehringer Ingelheim Service Portfolio
Figure 161 Boehringer Ingelheim SWOT Analysis
Figure 162 Catalent, Inc. Service/Product Portfolio
Figure 163 Catalent, Inc. Overall Financials, Million, 2019-2021
Figure 164 Catalent, Inc. Revenue (by Segment), Million, 2019-2021
Figure 165 Catalent, Inc. Revenue (by Region), Million, 2019-2021
Figure 166 Catalent, Inc. RD Expenditure, Million, 2019-2021
Figure 167 Catalent, Inc. SWOT Analysis
Figure 168 FUJIFILM Holdings Corporation Service/Product Portfolio
Figure 169 FUJIFILM Holdings Corporation Overall Financials, Million, 2018-2020
Figure 170 FUJIFILM Holdings Corporation Revenue (by Segment), Million, 2018-2020
Figure 171 FUJIFILM Holdings Corporation Revenue (by Region), Million, 2018-2020
Figure 172 FUJIFILM Holdings Corporation RD Expenditure, Million, 2018-2020
Figure 173 FUJIFILM Holdings Corporation SWOT Analysis
Figure 174 Danaher Corporation Service/Product Portfolio
Figure 175 Danaher Corporation Overall Financials, Million, 2018-2020
Figure 176 Danaher Corporation Revenue (by Segment), Million, 2018-2020
Figure 177 Danaher Corporation Revenue (by Region), Million, 2018-2020
Figure 178 Danaher Corporation RD Expenditure, Million, 2018-2020
Figure 179 Danaher Corporation SWOT Analysis
Figure 180 Genscript Biotech Corporation Service/Product Portfolio
Figure 181 Genscript Biotech Corporation Overall Financials, Million, 2018-2020
Figure 182 Genscript Biotech Corporation Revenue (by Segment), Million, 2018-2020
Figure 183 Genscript Biotech Corporation Revenue (by Region), Million, 2018-2020
Figure 184 Genscript Biotech Corporation RD Expenditure, Million, 2018-2020
Figure 185 Genscript Biotech Corporation SWOT Analysis
Figure 186 Lonza Group AG Service/Product Portfolio
Figure 187 Lonza Group AG Overall Financials, Million, 2018-2020
Figure 188 Lonza Group AG Revenue (by Segment), Million, 2018-2020
Figure 189 Lonza Group AG Revenue (by Region), Million, 2018-2020
Figure 190 Lonza Group AG RD Expenditure, Million, 2018-2020
Figure 191 Lonza Group AG SWOT Analysis
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
19
21
Figure 192 Merck KGaA Inc. Service/Product Portfolio
Figure 193 Merck KGaA Inc. Overall Financials, Million, 2018-2020
Figure 194 Merck KGaA Inc. Revenue (by Segment), Million, 2018-2020
Figure 195 Merck KGaA Inc. Revenue (by Region), Million, 2018-2020
Figure 196 Merck KGaA Inc. RD Expenditure, Million, 2018-2020
Figure 197 Merck KGaA Inc. SWOT Analysis
Figure 198 Oxford Biomedica plc Service/Product Portfolio
Figure 199 Oxford Biomedica plc Overall Financials, Million, 2018-2020
Figure 200 Oxford Biomedica plc Revenue (by Segment), Million, 2018-2020
Figure 201 Oxford Biomedica plc Revenue (by Region), Million, 2018-2020
Figure 202 Oxford Biomedica plc RD Expenditure, Million, 2018-2020
Figure 203 Oxford Biomedica plc SWOT Analysis
Figure 204 Sartorius AG Service/Product Portfolio
Figure 205 Sartorius AG Overall Financials, Million, 2018-2020
Figure 206 Sartorius AG Revenue (by Segment), Million, 2018-2020
Figure 207 Sartorius AG Revenue (by Region), Million, 2018-2020
Figure 208 Sartorius AG RD Expenditure, Million, 2018-2020
Figure 209 Sartorius AG SWOT Analysis
Figure 210 Takara Bio Inc. Service/Product Portfolio
Figure 211 Takara Bio Inc. Overall Financials, Million, 2018-2020
Figure 212 Takara Bio Inc. Revenue (by Segment), Million, 2018-2020
Figure 213 Takara Bio Inc. Revenue (by Region), Million, 2018-2020
Figure 214 Takara Bio Inc. RD Expenditure, Million, 2018-2020
Figure 215 Takara Bio Inc. SWOT Analysis
Figure 216 Thermo Fisher Scientific, Inc. Service/Product Portfolio
Figure 217 Thermo Fisher Scientific, Inc. Overall Financials, Million, 2018-2020
Figure 218 Thermo Fisher Scientific, Inc. Revenue (by Segment), Million, 2018-2020
Figure 219 Thermo Fisher Scientific, Inc. Revenue (by Region), Million, 2018-2020
Figure 220 Thermo Fisher Scientific, Inc. RD Expenditure, Million, 2018-2020
Figure 221 Thermo Fisher Scientific, Inc. SWOT Analysis
Figure 222 Wuxi AppTec Service/Product Portfolio
Figure 223 Wuxi AppTec Overall Financials, Million, 2018-2020
Figure 224 Wuxi AppTec Revenue (by Segment), Million, 2018-2020
Figure 225 Wuxi AppTec Revenue (by Region), Million, 2018-2020
Figure 226 Wuxi AppTec RD Expenditure, Million, 2018-2020
Figure 227 Wuxi AppTec SWOT Analysis
Figure 228 Acuitas Therapeutics Service/Product Portfolio
Figure 229 Acuitas Therapeutics SWOT Analysis
Figure 230 Evonik Industries AG Service/Product Portfolio
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
22
Figure 231 Evonik Industries AG Overall Financials, Million, 2018-2020
Figure 232 Evonik Industries AG Revenue (by Segment), Million, 2018-2020
Figure 233 Evonik Industries AG Revenue (by Region), Million, 2018-2020
Figure 234 Evonik Industries AG RD Expenditure, Million, 2018-2020
Figure 235 Evonik Industries AG SWOT Analysis
Figure 236 Exelead, Inc. Service/Product Portfolio
Figure 237 Exelead, Inc. SWOT Analysis
Figure 238 Entos Pharmaceuticals Service/Product Portfolio
Figure 239 Entos Pharmaceuticals SWOT Analysis
Figure 240 Genevant Sciences GmbH Service/Product Portfolio
Figure 241 Genevant Sciences GmbH SWOT Analysis
Figure 242 TT Scientific Corporation Service/Product Portfolio
Figure 243 TT Scientific Corporation SWOT Analysis
Figure 244 Moderna, Inc. Service/Product Portfolio
Figure 245 Moderna, Inc. Overall Financials, Million, 2018-2020
Figure 246 Moderna, Inc. Revenue (by Region), Million, 2018-2020
Figure 247 Moderna, Inc. RD Expenditure, Million, 2018-2020
Figure 248 Moderna, Inc. SWOT Analysis
Figure 249 CureVac N.V. Product Portfolio
Figure 250 CureVac N.V. Overall Financials, Million, 2018-2020
Figure 251 CureVac N.V. Revenue (by Region), Million, 2018-2020
Figure 252 CureVac N.V. RD Expenditure, Million, 2018-2020
Figure 253 CureVac N.V. SWOT Analysis
GLOBAL VIRAL AND NON- VIRAL VECTOR MANUFACTURING
MARKET
23
List of Tables
Leading Segments of the Global Viral and
Non-Viral Vector Manufacturing Market, 2020 and
2031 Advantages and Disadvantages of Viral
Vectors Advantages and Disadvantages of
Non-Viral Vectors COVID-19 Candidate Viral Vector
Vaccines in Clinical Stage (as of 31st July 2020)
COVID-19 Candidate Viral Vector Vaccines in
Preclinical Stage (as of 31 July 2020) Recent
Approvals for Gene Therapy Companies Offering
Gene Therapies and Their Cost Global Regulatory
Scenario Patents Related to Viral Vectors
(January 2018-February 2021) Patents Related to
Non-Viral Vectors (January 2018-February 2021)
Examples of Viral Vectors Used in Gene
Therapy List of Non-Viral Vector-Based Vaccines
against Infectious Diseases Features of Vectors
Used in Cardiovascular Therapy Examples of
Clinical Trials Using Viral Vec